Trial Profile
A Phase 2 Pharmacodynamic Trial of Ezogabine (Retigabine) on Neuronal Excitability in Amyotrophic Lateral Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Retigabine (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- 23 Nov 2020 Primary endpoint (Change in short-interval intracortical inhibition (SICI) measured by transcranial magnetic stimulation (TMS) after treatment with 900 mg/day) has been met, according to results published in the JAMA Neurology
- 23 Nov 2020 Primary endpoint (Change in short-interval intracortical inhibition (SICI) measured by transcranial magnetic stimulation (TMS) after treatment with 600 mg/day) has not been met, according to results published in the JAMA Neurology
- 23 Nov 2020 Results published in the JAMA Neurology